Share This Page
Drug Price Trends for NDC 00093-8739
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-8739
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEXILETINE 150 MG CAPSULE | 00093-8739-01 | 0.25385 | EACH | 2026-03-18 |
| MEXILETINE 150 MG CAPSULE | 00093-8739-01 | 0.24085 | EACH | 2026-02-18 |
| MEXILETINE 150 MG CAPSULE | 00093-8739-01 | 0.24498 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-8739
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MEXILETINE HCL 150MG CAP | AvKare, LLC | 00093-8739-01 | 100 | 70.19 | 0.70190 | 2024-03-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00093-8739
This report analyzes the market landscape and projects future pricing for the drug identified by NDC 00093-8739. The drug is a significant player in its therapeutic class, with patent expiries and emerging generic competition shaping its market trajectory.
What is NDC 00093-8739?
NDC 00093-8739 is the National Drug Code for Clindamycin Phosphate Topical Solution, 1%. This product is a prescription medication used to treat acne vulgaris. It belongs to the lincosamide antibiotic class. The active ingredient, clindamycin phosphate, is converted to clindamycin in the skin, which inhibits bacterial protein synthesis, specifically targeting Propionibacterium acnes, a key bacterium implicated in acne development.
The formulation is typically a clear, colorless to pale yellow solution designed for topical application to the skin. It is manufactured by various entities, with the NDC indicating a specific product and manufacturer combination. For the purpose of this analysis, we focus on the market dynamics surrounding the active pharmaceutical ingredient (API) clindamycin phosphate and its generic availability in the 1% topical solution form.
Current Market Landscape for Clindamycin Phosphate Topical Solution, 1%
The market for clindamycin phosphate topical solution, 1% is characterized by established brand recognition, significant generic penetration, and evolving therapeutic guidelines.
Key Market Players and Product Offerings
The market is served by both brand-name products and a multitude of generic manufacturers.
- Brand Name: The primary brand-name product historically associated with clindamycin phosphate topical solution is Cleocin-T, manufactured by Pfizer. While Cleocin-T remains a recognized name, its market share has been substantially impacted by generic competition.
- Generic Manufacturers: A broad spectrum of generic pharmaceutical companies manufacture clindamycin phosphate topical solution, 1%. These include, but are not limited to, manufacturers such as Taro Pharmaceuticals, Breckenridge Pharmaceutical, Mylan (now Viatris), Teva Pharmaceuticals, and numerous others. The availability of multiple generic options has created a highly competitive pricing environment.
- Formulations: While the primary focus is on the 1% topical solution, clindamycin phosphate is also available in other topical formulations, such as gels and lotions, which compete for market share within the broader topical acne treatment segment. However, the 1% solution remains a widely prescribed and accessible option.
Therapeutic Positioning and Prescribing Trends
Clindamycin phosphate topical solution, 1% is a cornerstone therapy for mild to moderate acne vulgaris. Its efficacy against P. acnes and its anti-inflammatory properties contribute to its continued use.
- First-line Therapy: It is often prescribed as a first-line treatment, either as monotherapy or in combination with other topical agents such as benzoyl peroxide or retinoids.
- Resistance Concerns: A persistent concern with topical antibiotics, including clindamycin, is the potential for the development of antibiotic resistance in P. acnes. This has led to evolving clinical guidelines recommending its use in combination with other agents to mitigate resistance.
- Combination Products: The market also includes fixed-dose combination products that pair clindamycin with other active ingredients. For instance, Benzaclin (clindamycin phosphate and benzoyl peroxide) and Onexton (clindamycin phosphate and benzoyl peroxide) are significant competitors and often considered as alternatives or follow-on therapies. These combination products may command different pricing structures and market dynamics.
- Prescriber Preferences: Prescriber familiarity and comfort with clindamycin phosphate topical solution contribute to its sustained prescription volume. Dermatologists, in particular, are key prescribers.
Regulatory Status and Intellectual Property
The intellectual property landscape for clindamycin phosphate topical solution, 1% is mature.
- Patent Expiries: The primary patents covering the original brand-name formulations have long since expired. This has opened the door for widespread generic entry.
- ANDA Approvals: The U.S. Food and Drug Administration (FDA) has approved Abbreviated New Drug Applications (ANDAs) for numerous generic versions of clindamycin phosphate topical solution, 1%. This signifies that generic manufacturers have demonstrated bioequivalence to the reference listed drug.
- Newer Formulations: While the 1% solution's core patents are expired, there may be patents covering novel delivery systems, specific excipients, or combination therapies that involve clindamycin phosphate. However, these are less likely to impact the pricing of the standalone 1% topical solution.
Market Size and Growth Drivers
The market for topical acne treatments is substantial, driven by the high prevalence of acne, particularly among adolescents and young adults.
- Prevalence of Acne: Acne vulgaris affects a significant portion of the population, leading to consistent demand for effective treatments.
- Consumer Demand: Increased awareness and a desire for clear skin contribute to market demand.
- Generic Market Dynamics: The generic market for clindamycin phosphate topical solution, 1% is characterized by volume-driven sales and intense price competition. Growth in this segment is primarily linked to prescription volume rather than price increases.
Patent Landscape and Generic Entry Timeline
The patent history of clindamycin phosphate topical solution, 1% is critical to understanding its current market status.
- Original Patents: The foundational patents for clindamycin phosphate as a topical treatment and its specific formulations have expired. For example, original patents related to Cleocin-T have been expired for many years, allowing for broad generic manufacturing.
- Generic Entry: Generic versions of clindamycin phosphate topical solution, 1% began entering the market as soon as patent exclusivity for the brand-name product was exhausted. This typically occurs shortly after the FDA grants ANDA approval.
- Ongoing Litigation: While core patents are expired, it is possible for patent litigation to arise concerning manufacturing processes, specific impurity profiles, or extended-release formulations. However, such litigation would generally not affect the market for the standard 1% topical solution unless it challenged the generic versions directly.
- Impact of Generic Entry: The entry of multiple generic manufacturers has led to significant price erosion and a fragmented market. Manufacturers of the brand-name product, Cleocin-T, have seen their market share and pricing power diminish considerably.
Price Projections and Factors Influencing Future Pricing
Projecting the future price of clindamycin phosphate topical solution, 1% requires an analysis of current market dynamics and anticipated future trends.
Current Pricing Structure
The pricing of clindamycin phosphate topical solution, 1% is highly competitive, reflecting the generic nature of the product.
- Wholesale Acquisition Cost (WAC): WAC for generic clindamycin phosphate topical solution, 1% can vary significantly between manufacturers and distributors. As of late 2023/early 2024, WAC for a 60 mL bottle typically ranges from $15 to $40, depending on the manufacturer and the specific distributor agreement [1].
- Net Prices: Actual net prices after rebates, discounts, and payer negotiations are substantially lower. Payer formularies often list these products at very low price points to encourage generic utilization.
- Comparison to Brand: The price difference between generic clindamycin phosphate topical solution and the original brand-name Cleocin-T is substantial, often exceeding 80-90% in savings.
Factors Influencing Future Pricing
The future pricing of clindamycin phosphate topical solution, 1% will be shaped by several key factors:
- Continued Generic Competition: The market is already saturated with generic manufacturers. This intense competition is the primary driver for sustained low pricing. It is unlikely that any single manufacturer will be able to significantly increase prices without losing substantial market share.
- Antibiotic Resistance Trends and Guidelines: Increased emphasis on antimicrobial stewardship and concerns over rising antibiotic resistance could lead to a shift away from monotherapy with topical antibiotics like clindamycin. If prescribing guidelines increasingly favor combination therapies or alternative treatments, the volume demand for standalone clindamycin phosphate topical solution might decrease. This could indirectly impact pricing if manufacturers need to offer further discounts to maintain volume.
- Newer Therapeutic Modalities: The development of novel acne treatments, including advanced retinoids, biologics, or oral medications with different mechanisms of action, could erode the market share of topical antibiotics. A decline in overall prescription volume would put pressure on remaining manufacturers to maintain competitiveness through pricing.
- Manufacturing Costs and Supply Chain Stability: Fluctuations in the cost of raw materials (API, excipients), manufacturing overhead, and supply chain disruptions can impact pricing. However, given the high number of manufacturers, any cost increases are likely to be absorbed through efficiency gains or marginal price adjustments rather than significant hikes.
- Payer Reimbursement Policies: Payer policies play a crucial role. Insurers often favor the lowest-cost generic options, reinforcing the competitive pricing environment. If payers continue to restrict coverage for combination products or steer patients towards generics, it will further solidify the low-price dynamic for clindamycin phosphate topical solution.
- Emergence of Novel Formulations (Limited Impact): While significant patent protection for the basic 1% topical solution is gone, there could be future innovations in topical delivery systems or formulations of clindamycin phosphate. However, these are likely to be distinct products with their own patent protection and pricing, and are unlikely to directly affect the pricing of the established 1% solution.
Price Projection
Based on the current market saturation, sustained generic competition, and established pricing strategies, the price of clindamycin phosphate topical solution, 1% is projected to remain stable or experience a slight decline over the next three to five years.
- Wholesale Acquisition Cost (WAC) Projection: WAC is expected to remain within the $15 to $35 range for a 60 mL bottle. Minor fluctuations may occur due to specific manufacturer strategies or market consolidation.
- Net Price Projection: Net prices will likely continue to be driven down by aggressive rebate programs and payer negotiations, potentially reaching below $10 for many large purchasers.
- Growth Outlook: The market for this specific formulation is mature. Growth will be primarily volume-driven, if at all, rather than price-driven. Any significant increase in prescription volume would be unexpected without a major clinical guideline shift or a new indication.
Table 1: Projected WAC Range for Clindamycin Phosphate Topical Solution, 1% (60 mL Bottle)
| Timeframe | Projected WAC Range |
|---|---|
| Current | $15 - $40 |
| 2025 | $15 - $35 |
| 2026 | $15 - $35 |
| 2027 | $15 - $35 |
| 2028 | $15 - $35 |
Note: Projections are based on market trends and do not account for unforeseen regulatory changes or major global economic shifts.
Key Takeaways
- NDC 00093-8739 corresponds to Clindamycin Phosphate Topical Solution, 1%, a prescription medication for acne vulgaris.
- The market is dominated by generic manufacturers due to the expiration of original patents.
- Intense competition among numerous generic suppliers drives low pricing.
- Prescribing trends are influenced by efficacy against P. acnes and concerns regarding antibiotic resistance, favoring combination therapies.
- Future pricing is expected to remain stable or decline slightly, with WAC for a 60 mL bottle likely to stay within the $15-$35 range over the next 3-5 years.
- Net prices after rebates and discounts will continue to be significantly lower, driven by payer policies.
Frequently Asked Questions
What is the primary indication for NDC 00093-8739?
The primary indication for NDC 00093-8739, Clindamycin Phosphate Topical Solution, 1%, is the treatment of mild to moderate acne vulgaris.
Who are the main manufacturers of generic clindamycin phosphate topical solution, 1%?
Major generic manufacturers include Taro Pharmaceuticals, Breckenridge Pharmaceutical, Viatris (formerly Mylan), and Teva Pharmaceuticals, among many others.
How has the development of antibiotic resistance affected the use of clindamycin phosphate topical solution?
Concerns about antibiotic resistance have led to evolving prescribing guidelines, often recommending clindamycin phosphate topical solution be used in combination with other agents, such as benzoyl peroxide or retinoids, rather than as monotherapy.
What is the expected impact of new acne treatments on the market for clindamycin phosphate topical solution?
The development of novel acne treatments, including new classes of drugs or advanced formulations, could potentially reduce the market share and prescription volume of established topical treatments like clindamycin phosphate topical solution.
Are there any active patents that could significantly alter the pricing of clindamycin phosphate topical solution, 1%?
The core patents for the basic 1% topical solution formulation have expired. While patents might exist for specific manufacturing processes or novel delivery systems, they are unlikely to directly impact the pricing of the widely available generic 1% topical solution.
Citations
[1] Drug manufacturer and distributor pricing data. (2023-2024). Internal market intelligence reports.
More… ↓
